Officials with the FDA have approved crisaborole (Eucrisa) ointment, 2%, for use in children as young as 3 months of age with mild-to-moderate atopic dermatitis.
DW Weekly: FDA approves crisaborole for AD patients as young as three months
![](https://aad.awarenessmonthly.com/consumer/wp-content/uploads/2020/09/1620-fda-approved-1600x1333.jpg)
Officials with the FDA have approved crisaborole (Eucrisa) ointment, 2%, for use in children as young as 3 months of age with mild-to-moderate atopic dermatitis.